Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Plastic Surgery
Erschienen in: European Journal of Plastic Surgery 2/2012

01.02.2012 | Original Paper

An overview of current biomaterials in aesthetic soft tissue augmentation

verfasst von: H. Ryssel, G. Germann, E. Koellensperger

Erschienen in: European Journal of Plastic Surgery | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Today an increasing number of patients seek aesthetic improvement through minimally invasive procedures, and interest in soft tissue augmentation and filling agents is rising steadily. However, a thorough understanding of these substances, their indications and contraindications, as well as a profound knowledge of different implantation techniques is essential to provide an aesthetically pleasing result for the patient. This presentation gives an overview of the current injectable biomaterials, their major indications, advantages and disadvantages, with focus on collagen, hyaluronic acid, poly-l-lactide, and autologous fat grafting.
Literatur
1.
Neuber F (1893) Fettransplantation. Chir Kongr Verhandl Dsch Gesellch Chir 22:66
2.
Klein AW, Elson ML (2000) The history of substances for soft tissue augmentation. Dermatol Surg 26:1096–1105PubMedCrossRef
3.
Baumann L (2002) Soft tissue augmentation. In: Baumann L (ed) Cosmetic dermatology principles and practice. McGraw-Hill, New York, pp 155–172
4.
Clark DP, Hanke CW, Swanson NA (1989) Dermal implants: safety of products injected for soft tissue augmentation. J Am Acad Dermatol 21:992–998PubMedCrossRef
5.
Klein AW (1992) Injectable collagen. In: Moschells SL, Hurley HJ (eds) Dermatology. W.B. Saunders Co., Philadelphia, pp 2455–2461
6.
Hanke CW, Coleman WP III (1997) Dermal filler substances. In: Asken S, Alt TH, Hanke CW, Coleman WP III (eds) Cosmetic surgery of the skin. Mosby, St. Louis, pp 217–230
7.
Hanke CW, Higley HR, Jolivette DM, Swanson NA, Stegman SJ (1991) Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol 25:319–326PubMedCrossRef
8.
Elson ML (1989) The role of skin testing in the use of collagen injectable materials. J Dermatol Surg Oncol 15:301–303PubMed
9.
Stegman SJ, Chu S, Armstrong RC (1988) Adverse reactions to bovine collagen implant: clinical and histologic features. J Dermatol Surg Oncol 14:39–48
10.
Castrow FF 2nd, Krull EA (1983) Injectable collagen implant–update. J Am Acad Dermatol 9:889–893PubMedCrossRef
11.
Siegle RJ, McCoy JP Jr, Schade W, Swanson NA (1984) Intradermal implantation of bovine collagen. Humoral immune responses associated with clinical reactions. Arch Dermatol 120:183–187PubMedCrossRef
12.
Klein AW, Rish DC (1984) Injectable collagen update. J Dermatol Surg Oncol 10:519–522PubMed
13.
Klein AW (1989) In favor of double testing. J Dermatol Surg Oncol 15:263PubMed
14.
Baumann LS, Kerdel F (1999) The treatment of bovine collagen allergy with cyclosporin. Dermatol Surg 25:247–249PubMedCrossRef
15.
Moody BR, Sengelmann RD (2001) Topical tacrolimus in the treatment of bovine collagen hypersensitivity. Dermatol Surg 27:789–791PubMedCrossRef
16.
Cukier J, Beauchamp RA, Spindler JS, Spindler S, Lorenzo C, Trentham DE (1993) Association between bovine collagen dermal implants and a dermatomyositis or a polymyositis-like syndrome. Ann Intern Med 118:920–928PubMed
17.
Hanke CW, Thomas JA, Lee WT, Jolivette DM, Rosenberg MJ (1996) Risk assessment of polymyositis/dermatomyositis after treatment with injectable bovine collagen implants. J Am Acad Dermatol 34:450–454PubMedCrossRef
18.
Rosenberg MJ, Reichlin M (1994) Is there an association between injectable collagen and polymyositis/dermatomyositis? Arthritis Rheum 37:747–753PubMedCrossRef
19.
Elson ML (1993) Injectable collagen and autoimmune disease. J Dermatol Surg Oncol 19:165–168 discussion 170PubMed
20.
Lemperle G, Gauthier-Hazan N, Lemperle M (1998) PMMA-microspheres (Artecoll) for long-lasting correction of wrinkles: refinements and statistical results. Aesthetic Plast Surg 22:356–365PubMedCrossRef
21.
Cohen SR, Holmes RE (2004) Artecoll: a long-lasting injectable wrinkle filler material: report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 114:964–976 discussion 977–979PubMedCrossRef
22.
Bauman L (2004) CosmoDerm/CosmoPlast (human bioengineered collagen) for the aging face. Facial Plast Surg 20:125–128PubMedCrossRef
23.
Perret S, Eble JA, Siljander PR et al (2003) Prolyl hydroxylation of collagen type I is required for efficient binding to integrin alpha 1 beta 1 and platelet glycoprotein VI but not to alpha 2 beta 1. J Biol Chem 278:29873–29879PubMedCrossRef
24.
Okada S, Hagan JB, Kato M et al (1998) Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol 160:4010–4017PubMed
25.
Menon NG et al (2003) Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model. Ann Plast Surg 50:523–527PubMedCrossRef
26.
Silverman RP et al (2004) Ventral hernia repair using allogenic acellular dermal matrix in a swine model. Hernia 8:336–342PubMedCrossRef
27.
Lattari V, Jones LM, Varcelotti JR, Latenser BA, Sherman HF, Barrette RR (1997) The use of a permanent dermal allograft in full-thickness burns of the hand and foot: a report of three cases. J Burn Care Rehabil 18:147–155PubMedCrossRef
28.
Sclafani AP, Romo T, Jacono AA III (2002) Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg 4:252–257PubMedCrossRef
29.
Hanke CW, Coleman WP III (1997) Dermal filler substances. In: Asken S, Alt TH, Hanke CW, Coleman WP III (eds) Cosmetic surgery of the skin. Mosby, St. Louis, pp 217–230
30.
Sutherland I (1988) Novel and established applications of microbial polysaccharides. Trends Biotechnol 16:41–46CrossRef
31.
Fink RM, Lengfelder E (1987) Hyaluronic acid degradation by ascorbic acid and influence of iron. Free Rad Res Comm 3:85–92CrossRef
32.
Monheit GD (2004) “Hylaform: a new hyaluronic acid filler” in soft tissue augmentation. Facial Plast Surg 20:153–157PubMedCrossRef
33.
Olenius M (1988) The first clinical study using a new biodegradable implant for treatment of lips, wrinkles, and folds. Aesthetic Plast Surg 22:97–101CrossRef
34.
Duranti F, Salti G, Bovani B, Calandra M, Rosati ML (1998) Injectable hyaluronic acid gel for soft tissue augmentation: a clinical and histological study. Dermatol Surg 24:1317–1325PubMedCrossRef
35.
Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S (2003) A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 29:588–595PubMedCrossRef
36.
Lupton JR, Alster TS (2000) Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 26:135–137PubMedCrossRef
37.
Lowe NJ, Maxwell CA, Patanaik R (2005) Adverse reactions to dermal fillers: review. Dermatol Surg 31:1616–1625PubMed
38.
Micheels P (2002) Human anti-hyaluronic acid antibodies: is it possible? Dermatol Surg 28:359–360
39.
Friedman PM, Mafung EA, Kauvar AN, Gerronemus RG (2002) Safety data non-injectable non-animal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 28:491–494PubMedCrossRef
40.
Athanasiou KA, Niederauer GG, Agrawal CM, Landsman AS (1995) Applications of biodegradable lactides and glycolides in podiatry. Clin Podiatr Med Surg 12:475–495PubMed
41.
Tonnard PL, Verpaele AM (2004) The MACS-Lift. Short-scan rhyfidectomy. Quality Medical Publishing, St. Louis
42.
Brady JM, Cutright DE, Miller RA, Barristone GC (1973) Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res 7:155–166PubMedCrossRef
43.
Moyle GJ, Lysakova L, Brown S et al (2004) A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 5:82–87PubMedCrossRef
44.
Humble G, Mest D (2004) Soft tissue augmentation using sculptra. Facial Plast Surg 20:157–163PubMedCrossRef
45.
Lemperle G, Morhenn VB, Pestonjamasp V, Gallo RL (2004) Migration studies and histology of injectable microspheres of different sizes in mice. Plast Reconstr Surg 113:1380–1390PubMedCrossRef
46.
Bergsma JE, Rozema FR, Bos RR, Boering G, de Bruijn WC, Pennings AJ (1995) In vivo degradation and biocompatibility study of in vitro pre-degraded as-polymerized polyactide particles. Biomaterials 16:267–274PubMedCrossRef
47.
Christensen L, Breiting V, Janssen M, Vuust J, Hogdall E (2005) Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 29:34–48PubMedCrossRef
48.
Burgess CM, Quiroga RM (2005) Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 52:233–239PubMedCrossRef
49.
Lemperle G, Morhenn V, Charrier U (2003) Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg 27:354–366 discussion 367PubMedCrossRef
50.
Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK (1993) Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 27:1135–1148PubMedCrossRef
51.
Moe KS, Weisman RA (2001) Resorbable fixation in facial plastic and head and neck reconstructive surgery: an initial report on polylactic acid implants. Laryngoscope 111:1697–1701PubMedCrossRef
52.
Woerle B, Hanke CW, Sattler G (2004) Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 3:385–389PubMed
53.
Lombardi T, Samson J, Plantier F, Husson C, Kuffer R (2004) Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med 33:115–120PubMedCrossRef
54.
55.
Spenlehauer G, Vert M, Benoit JP, Boddaert A (1989) In vitro and in vivo degradation of poly (D,L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials 10:557–563PubMedCrossRef
56.
Lichtenstein KA, Ward DJ, Moorman AC et al (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15:1389–1398PubMedCrossRef
57.
James J, Carruthers A, Carruthers J (2002) HIV-associated facial lipoatrophy. Dermatol Surg 28:979–986PubMedCrossRef
58.
Collins E, Wagner C, Walmsley S (2000) Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 10:546–550PubMed
59.
Amard P, Saint Marc T, Katz P (2000) The effects of polylactic acid (NewFill) as therapy for lipoatrophy of the face. Abstract p. 94. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, September 13–15
60.
Lafaurie M, Dolivo M, Boulu D et al (2003) Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients. Poster presentaion: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10–14
61.
Valantin MA, Aubron-Olivier C, Ghosn J et al (2003) Polylactic acid implants (NewFill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17:2471–2477PubMedCrossRef
62.
Mest D, Humble G (2004) Safety and efficiency of poly-L-lactic acid (Sculptra) injections for patients with HIV-associated facial lipoatrophy. Antiviral Ther 9:L36
63.
Laglenne S (2000) Un nouveau produit de comblement des rides, entirerment resorbable. Dermatologie 54:30–33
64.
Bauer U (2004) Improvement of facial aesthetics at 40 months with injectable poly-L-lactic acid (PLLA). Poster 164. 17th Congress of the International Society of Aesthetic Plastic Surgery in Houston, Texas, August
65.
Lexer E (1910) Freie Fettransplantation. Dtsch Med Wochenschr 36:640
66.
Illouz Y (1986) The fat cell “graft” a new technique to fill depressions. Plast Reconstr Surg 78:122PubMedCrossRef
67.
Fournier P (1989) Facial recontouring with fat grafting. Dermatol Clin 8:523
68.
Klein JA (1990) Tumescent technique for regional anaesthesia permits lidocaine doses of 35 mg/kg for liposuction. J Dermatol Surg Oncol 16:248–263PubMed
69.
Coleman WP III, Lawrence N, Sherman RN et al (1993) Autologous collagen: lipocytic dermal augmentation–a histopathologic study. J Dermatol Surg Oncol 19:1032PubMed
70.
Coleman SR (1997) Facial recontouring with lipostructure. Clin Plastic Surg 24:347–367
71.
Peer LA (1950) Loss of weight and volume in human fat grafts with postulation of "cell survival theory". Plast Reconstr Surg 5:217CrossRef
72.
Billings E Jr, May JW Jr (1989) Historical review and present status of free fat graft autotransplantation in plastic and reconstructive surgery. Plast Reconstr Surg 83(2):368–381PubMedCrossRef
73.
Ersek RA (1991) Transplantation of purified autologous fat: a 3-year follow-up is disappointing. Plast Reconstr Surg 87(2):219–227 discussion 228PubMedCrossRef
74.
Sommer B, Sattler G (2000) Current concepts of fat graft survival: histology of aspirated adipose tissue and review of the literature. Dermatol Surg 26:1159–1166PubMedCrossRef
75.
Van R, Roncari D (2004) Complete differentiation of adipocyte precursors: a culture system for studying the cellular nature of adipose tissue. Cell Tissue Res 181:197–203
76.
Van RL, Roncari DA (1978) Complete differentiation of adipocyte precursors. A culture system for studying the cellular nature of adipose tissue. Cell Tissue Res 195(2):317–329PubMed
77.
Billings E Jr, May JW Jr (1989) Historical review and present status of free fat graft autotransplantation in plastic and reconstructive surgery. Plast Reconstr Surg 83(2):368–381PubMedCrossRef
78.
Koellensperger E et al (2006) Human serum from platelet-poor plasma for the culture of primary human preadipocytes. Stem Cells 24:1218–1225PubMedCrossRef
79.
Smahel J (1989) Experimental implantation of adipose tissue fragments. Br J Plast Surg 42(2):207–211PubMedCrossRef
80.
Dillerud E (1990) Abdominoplasty combined with suction lipoplasty: a study of complications, revisions, and risk factors in 487 cases. Ann Plast Surg 25:333–338PubMedCrossRef
81.
Brüner S, Deb R, Germann G (2003) Konservative Faltenbehandlung in der Hand des Plastischen Chirurgen. Chirurg 74:815–820PubMedCrossRef
Metadaten
Titel
An overview of current biomaterials in aesthetic soft tissue augmentation
verfasst von
H. Ryssel
G. Germann
E. Koellensperger
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Plastic Surgery / Ausgabe 2/2012
Print ISSN: 0930-343X
Elektronische ISSN: 1435-0130
DOI
https://doi.org/10.1007/s00238-008-0251-1

Weitere Artikel der Ausgabe 2/2012

European Journal of Plastic Surgery 2/2012 Zur Ausgabe

Case Report

Self-inflicted formic acid burn: rare form of acid burn (two case reports)

Original Paper

Nanofiber-based scaffolds for tissue engineering

Case Report

One stage reconstruction of the upper eyelid after excision of an extensive blue nevus—case report

Case Report

Lower eyelid reconstruction with tarsoconjunctival flap in a xeroderma pigmentosum patient

Case Report

ARDS following flexor sheath infection: a case report

Original Paper

Long-term results of craniofacial implantation: a return to methyl methacrylate

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.